In this exclusive interview Kenneth Barr, SVP of Discovery Research at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery.
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
